Skip to content
Subscriber Only
Technology
Prognosis

Gilead Tumbles After Latest Data Leak on Virus Drug Trials

  • Drugmaker and doctor involved dispute that trial was a failure
  • S&P 500 briefly gives up gains after report on China trial
Video player cover image
Dr. Joseph Weinstein, Steward Health Care System chief medical officer, says it's too early to tell if the Covid-19 drug Remdesivir does not work.Source: Bloomberg)
Updated on

Gilead Sciences Inc. shares were whipsawed for the second time in a week after a summary of a Chinese trial of its Covid-19 drug appeared to show that it was a failure.

The synopsis, which the company and a scientist working on the trial said didn’t fairly represent the actual results, saw Gilead’s shares closed down 4.3% to $77.78 on Thursday in New York. The broader market fell as well, with the S&P 500 ending down 0.05%.